RXi Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to Samcyprone (diphenylcylcopropenone, DPCP) for the treatment of malignant melanoma Stage IIb to IV.

Samcyprone is a topical immunomodulating agent under clinical development for the treatment of warts, alopecia areata and cutaneous metastases of melanoma. The mechanism of action for treatment cutaneous metastases of melanoma involves elicitation of an immune response in the skin that subsequently causes destruction of the cutaneous tumor.

RELATED: Keytruda Results May Halt Melanoma Trial Early

Currently, a clinical trial in cutaneous metastases of melanoma, as well as a new investigator sponsored clinical trial in alopecia areata are ongoing. In addition, RXi plans to initiate a Phase 2a clinical trial in warts for Samcyprone by the end of 2015.

For more information visit RXiPharma.com.